Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. - Wikidata - wikimedia - TriplyDB

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

http://www.wikidata.org/entity/Q45947406

about

Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma Neuroblastoma Stem cell transplantation for neuroblastoma Neuroblastoma: issues in transplantation Overview and recent advances in the treatment of neuroblastoma.Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.Genetically InFormed therapies--a "GIFT" for children with cancer Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.Promising therapeutic targets in neuroblastoma Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma Targeted radionuclide therapy.Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.

P2860

Q24201280-05BE919B-59FB-4888-A12A-752F16062604 Q24617733-46DD6607-B69B-49A7-AE67-BA4F0ADCEA18 Q24629221-309F8ED3-EF3E-460A-8E75-07317B73671C Q27008197-E6ACBE30-0B38-46E0-B145-F4BFD915D896 Q30238693-32813792-F9F6-43F4-A542-93F417947826 Q33394925-D3981DEC-FF61-4880-AA2E-D1E8FFD9A8C3 Q33409568-9454419A-8BEA-4AE4-84EE-57B7F7C79907 Q33419558-08628FE4-8DD0-4B0E-9303-198EC407013A Q33419875-0FD95830-0AEC-4CA0-AA54-784D94327B00 Q33420546-3FE0020A-FD73-4F44-95F5-34D052FBE4C3 Q33427090-0D6B3DA6-5731-4EA2-A4FA-4C6C8DE5637C Q33429535-F6EFCC4B-C2E7-4519-97CC-1EF17434B7C8 Q33691441-1898651C-7B31-4505-8556-4B47ADAA170D Q33834340-80ECE830-465B-4708-B311-02052FCFAF21 Q33887843-8EAE0891-7FA5-45AD-A8F6-F8BB1ACACDFF Q33964937-2AAF898E-B028-4EB8-845B-B446B511496A Q34117552-96B8FAAC-CF10-454C-B1CD-69B53D6E8867 Q34270304-8CA420A8-A6B8-4964-AB3B-171C189E6C8A Q34310934-950BAC6E-AEA5-4C24-A570-AC553A320B1C Q34424834-2C129386-9D30-4CDD-8366-42DF07EFF6F0 Q34576380-FBC6CC3D-CDD4-4CCB-8197-43BFC758877B Q34589401-E77E6495-EC75-44EE-98A3-22DB6E998328 Q35074813-168FE2F5-8F54-4791-A0DD-7539DDF133A5 Q35077703-76891361-28D5-4636-915D-2899E81CB0EF Q35109012-9D2D5789-C546-46B7-A28A-4AC7B9652F4E Q35627829-6A7FF754-3F67-43AF-BDCB-3664AEAC4488 Q35637861-6E468F08-D812-40E4-AD8A-102A8681738D Q36013113-BE525AB6-A693-4F1E-BDD5-B2AB41781E5A Q36055313-4EDC3389-1813-4410-A164-2A8D679D9238 Q36167173-DE0480E7-F398-478C-98AC-CCF49902B42A Q36294179-9295A5B6-100E-4670-8844-E5CEF5CAF476 Q36353230-A32AFCC3-E078-45B1-9CB3-766AAB8875EA Q36411942-29396CC5-C2A1-4571-9B80-7BCDE6BCBEC4 Q36510103-8774703B-C6A2-4294-B0F6-2D7D7F4C068B Q36782374-F4436F91-4E24-46A1-A2D6-4BC2D15A6C92 Q37078231-FBE9DC90-D5E2-4E62-922E-E3B3D2B334F2 Q37130228-322B953F-78AB-425E-AD0B-347C3773C1E6 Q37148148-3B815F3F-A0CC-4790-8313-8A2D7CAD13C6 Q37334748-6DCC85D1-FCC4-4213-9830-59545E148269 Q37411657-BF5621B1-93D4-4B75-8CB0-8ACFD02B1A92

P2860

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

http://www.wikidata.org/entity/Q45947406

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Phase II study on the effect o ...... y in refractory neuroblastoma.

@en

Phase II study on the effect o ...... y in refractory neuroblastoma.

@nl

type

label

Phase II study on the effect o ...... y in refractory neuroblastoma.

@en

Phase II study on the effect o ...... y in refractory neuroblastoma.

@nl

altLabel

Phase II study on the effect o ...... py in refractory neuroblastoma

@en

prefLabel

Phase II study on the effect o ...... y in refractory neuroblastoma.

@en

Phase II study on the effect o ...... y in refractory neuroblastoma.

@nl

P1433

Q45947406-AE33A739-55A3-4818-897C-68C6A73C403E

P1476

Q45947406-68F0CE86-BBD2-403F-AF85-D1A59C73CCFE

P2093

Q45947406-0B6B15F3-0D2A-469D-8167-90FAFFA2882F

Q45947406-15F64363-797F-4203-8174-7D28CEF59628

Q45947406-1FCCDC4E-F8C6-4284-BCE8-E6FFD32C4D5A

Q45947406-2B7F146F-CE39-47F9-BFC8-E36A6D600960

Q45947406-2C0F9355-E1CF-4BB0-A0C2-0CB2928653A3

Q45947406-5565930E-3005-40A3-B28F-E2C4024D6833

Q45947406-97AF12F7-56D3-406D-8712-E7D195DD0157

Q45947406-CD546950-E30B-40A3-9DE9-109B77035846

Q45947406-D929DF92-F87A-4190-A0C7-873F670F39BF

Q45947406-DFAEA0B5-39BF-43A9-B2CB-7FB24D0FDDE6

P304

Q45947406-26E545A2-0E30-4947-8261-4BE8F6F3A78C

P31

Q45947406-335D7514-1060-448A-AA80-0146D548FED3

P356

Q45947406-9190945B-1BF2-4FDC-B233-EBDD12BEC94C

P407

Q45947406-ACC9D7AB-51B9-4043-A72F-946BF5BC5680

P433

Q45947406-C94314F5-9878-4B92-A0B4-608A7381596B

P478

Q45947406-C1AB63BE-5CD6-4CD7-ACEC-98E903BF831E

P577

Q45947406-B823BFB0-2A2A-4C4F-B186-223DA2CB6CF5

P698

Q45947406-DBEDB146-0BB3-4E9B-AE5F-D8B55BDFA753

P356

JCO.2006.09.3484

P1433

Journal of Clinical Oncology

P1476

Phase II study on the effect o ...... y in refractory neuroblastoma.

@en

P2093

Alekist Quach

http://www.w3.org/2001/XMLSchema#string

Gregory Yanik

http://www.w3.org/2001/XMLSchema#string

Janet Veatch

http://www.w3.org/2001/XMLSchema#string

John Huberty

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Julia Messina

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

Leslie S Kersun

http://www.w3.org/2001/XMLSchema#string

Patricia Brophy

http://www.w3.org/2001/XMLSchema#string

Randall A Hawkins

http://www.w3.org/2001/XMLSchema#string

P304

1054-1060

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.09.3484

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17369569

http://www.w3.org/2001/XMLSchema#string